Virios Therapeutics (NASDAQ:VIRI) Trading Up 5.6% – Still a Buy?

Virios Therapeutics, Inc. (NASDAQ:VIRI) traded up 5.6% during trading on Wednesday . The stock traded as high as $3.1528 and last traded at $3.01. 116,143 shares traded hands during trading, a decline of 89% from the average session volume of 1,049,645 shares. The stock had previously closed at $2.85.

Virios Therapeutics Stock Up 5.6%

The stock has a market capitalization of $57.97 million, a P/E ratio of -11.15 and a beta of 1.58. The stock has a 50 day simple moving average of $5.34 and a two-hundred day simple moving average of $5.30.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.

The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.